Universität zu Köln

Allo, Gabriel, Can, Ahu Damla, Wahba, Roger, Vogel, Nils, Goeser, Tobias, Kutting, Fabian and Waldschmidt, Dirk (2022). Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers. Mol. Clin. Oncol., 16 (2). ATHENS: SPANDIDOS PUBL LTD. ISSN 2049-9469

Full text not available from this repository.

Abstract

Biliary tract cancers (BTC) are rare but aggressive. Due to limited anti-tumor effects of current second- and later-line treatment regimens, novel treatment options are required. Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil (FOLFnal-IRI) achieved promising results as a second-line treatment in patients with pancreatic cancer, warranting further investigation in BTC. In the present study, a retrospective analysis of patients receiving FOLFnal-IRI after initial platinum-based chemotherapy for advanced BTC between January 2016 and August 2020 at the University Hospital Cologne (Cologne, Germany) was performed. A total of 11 patients were identified who met the inclusion criteria. A total of 4 patients (36.4%) were female and the median age was 54 years. The proportion of patients suffering from gallbladder carcinoma, intrahepatic and extrahepatic cholangiocarcinoma was 18.2, 63.6 and 9.1%, respectively. Furthermore, 7 patients (63.6%) received FOLFnal-IRI as their second-, 3 (27.3%) as third- and one (9.1%) as their fourth-line therapy. The disease control rate was 54.5% and 3 grade III toxicities were recorded. Progression-free survival and overall survival (OS) after initiation of FOLFnal-IRI was 5.1 and 12.4 months, respectively. OS after initial diagnosis was 24.7 months. FOLFnal-IRI demonstrated promising antitumor potential with an acceptable safety profile as a subsequent therapy regimen in advanced biliary tract malignancies. Further randomized controlled trials of its value as a treatment option for BTC appear justified.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Allo, Gabriel UNSPECIFIED UNSPECIFIED UNSPECIFIED Can, Ahu Damla UNSPECIFIED UNSPECIFIED UNSPECIFIED Wahba, Roger UNSPECIFIED UNSPECIFIED UNSPECIFIED Vogel, Nils UNSPECIFIED UNSPECIFIED UNSPECIFIED Goeser, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Kutting, Fabian UNSPECIFIED UNSPECIFIED UNSPECIFIED Waldschmidt, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-660608
DOI:	10.3892/mco.2021.2485
Journal or Publication Title:	Mol. Clin. Oncol.
Volume:	16
Number:	2
Date:	2022
Publisher:	SPANDIDOS PUBL LTD
Place of Publication:	ATHENS
ISSN:	2049-9469
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language 2ND-LINE THERAPY; PHASE-II; CHOLANGIOCARCINOMA; MULTICENTER; CHEMOTHERAPY; GEMCITABINE; CISPLATIN; FOLFIRI; TRENDS; SN-38 Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66060